GlaxoSmithKline approves sale of Vemgal plant
Pharma

GlaxoSmithKline approves sale of Vemgal plant

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS

  • By ICN Group | April 05, 2021

The Board of Directors of GlaxoSmithKline Pharmaceuticals Limited has approved the sale of company's manufacturing facility together with the land, plant and machinery, assets, software and equipment located at Vemgal, Karnataka to Hetero Labs Limited.

The transaction is subject to receipt of all statutory approvals from the concerned authorities and members of the company and signing of the definitive documents between the company and Hetero Labs Limited in this regard.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

Hetero has a strong global presence in over 126 countries and focuses on making affordable medicines accessible to patients worldwide.

Other Related stories

Startup

Chemical

Petrochemical

Digitization

Gas